Do PAI-1 and vitronectin promote or inhibit neointima formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 12, 2002, Pages 1943-1945

  Konstantinides, Stavros ^a   Schäfer, Katrin ^a   Loskutoff, David J ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; FIBRIN; HIRUDIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CAROTID ARTERY LIGATION; CELL MIGRATION; EDITORIAL; FIBRIN CLOT; FIBRINOLYSIS; GENE EXPRESSION REGULATION; MORPHOMETRICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RESTENOSIS; SMOOTH MUSCLE FIBER;

ANIMALS; FIBRINOLYSIS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUNICA INTIMA; VITRONECTIN;

EID: 0036924418     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000047462.65341.22     Document Type: Editorial

References (37)

1. de Waard V, Arkenbout K. Carmeliet P, Lindner P, Pannekoek H. Plasminogen activator inhibitor-1 and vitronectin protect against stenosis in a murine carotid ligation model. Arterioscler Thromb Vasc Biol. 2002;22:1978-1983.
2. Peng L, Bhatia N, Parker AC, Zhu Y, Fay WP. Endogenous vitronectin and plasminogen activator inhibitor-I promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol. 2002;22:934-939.
3. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehali L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-2247.
4. Held C, Hjemdahl P, Rehnqvist N, Wallen NH, Bjorkander I, Eriksson SV, Forslund L, Wiman B. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol: Results from the angina prognosis study in Stockholm. Circulation. 1997;95:2380-2386.
5. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
6. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type I in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients. A potential factor predisposing to thrombosis and its persistence. Circulation. 1998;97:2213-2221.
7. Robbie LA, Booth NA, Brown PAJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 1996;16:539-545.
8. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998-7002.
9. Schäfer K, Müller K, Hecke A, Riedel C, Loskutoff DJ, Konstantinides S. Enhanced thrombotic response and accelerated atherogenesis after arterial injury in apolipoprotein E-knockout mice. Circulation 2001;104(Suppl): II-242. Abstract.
10. Sawa H, Lundgren C, Sobel BE, Fujii S. Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: A potential progenitor of restenosis. J Am Coll Cardiol. 1994;24:1742-1748.
11. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-I expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:556-562.
12. Allison BA, Nilsson L, Karpe F, Hamsten A, Eriksson P. Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:1354-1360.
13. Dichtl W, Stiko A, Eriksson P, Goncalves I, Calara F, Banfi C, Ares MP, Hamsten A, Nilsson J. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:3025-3032.
14. Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, Butcher M, Weitz JI. Type I plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem. 2000;275:19788-19794.
15. Stoop AA, Lupu F, Pannekoek H. Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. Arterioscler Thromb Vasc Biol. 2000;20:1143-1149.
16. Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1: Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem. 2001;276:15567-15570.
17. Dufourcq P, Louis H, Moreau C, Daret D, Boisseau MR, Lamazière JMD, Bonnet J. Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque. Arterioscler Thromb Vasc Biol. 1998;18:168-176.
18. Van Aken BE, Seiffert D, Thinnes T, Loskutoff DJ. Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol. 1997;107:313-320.
19. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
20. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262-1275.
21. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, Virrnani R. Healed plaque ruptures and sudden coronary death: Evidence that subclinical rupture has a role in plaque progression. Circulation. 2001;103:934-940.
22. Schäfer K, Konstantinides S, Riedel C, Thinnes T, Müller K, Dellas C, Hasenfuss G, Loskutoff DJ. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator. Circulation. 2002;106:1847-1852.
23. Konstantinides S, Schäfer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi following vascular injury in mice. Circulation. 2001;103:576-583.
24. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood. 2000;95:577-580.
25. Zhu Y, Farrehi PM, Fay WP. Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation. 2001;103:3105-3110.
26. Ploplis V, Cornelissen I, Sandoval-Cooper MJ, Weeks L, Noria FA, Castellino FJ. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol. 2001;158:107-117.
27. DeYoung MB, Tom C, Dichek DA. Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation. 2001;104:1972-1977.
28. Carmeliet P, Moons L, Dewerchin M, Rosenberg S, Herbert J-M, Lupu F, Collen D. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol. 1998;140:233-245.
29. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-I in arterial wound healing and neointima formation: A gene targeting and gene transfer study in mice. Circulation. 1997;96:3180-3191.
30. Carmeliet P, Moons L, Herbert JM, Crawley J, Lupu F, Lijnen R, Collen D. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res. 1997;81:829-839.
31. Lijnen HR, van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol. 1998;18:1035-1045.
32. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Degen JL. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest. 1998;101:1184-1194.
33. Loskutoff DJ, Quigley JP. PAI-1, fibrosis and the elusive provisional fibrin matrix. J Clin Invest. 2000;106:1441-1443.
34. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol. 1996;134:1563-1571.
35. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 1996;383:441-443.
36. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol. 1997;17:2238-2244.
37. Kawasaki T, Dewerchin M, Lijnen HR, Vreys I, Vermylen J, Hoylaerts MF. Mouse carotid artery ligation induces platelet-leukocyte-dependent luminal fibrin, required for neointima development. Circ Res. 2001;88:159-166.